Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6502279 | 0.98 | NAAA (0.62) | NAAAEPHX2KEAP1NFE2L2EPHX1 | |
| SCHEMBL2678008 | 0.98 | NAAA (0.62) | NAAAEPHX2KEAP1NFE2L2EPHX1 | |
| SCHEMBL9831292 | 0.94 | NAAA (0.62) | NAAAEPHX2KEAP1NFE2L2EPHX1 | |
| SCHEMBL9830181 | 0.93 | NAAA (0.65) | NAAAEPHX2KEAP1NFE2L2EPHX1 | |
| SCHEMBL9829575 | 0.93 | NAAA (0.65) | NAAAEPHX2KEAP1NFE2L2EPHX1 | |
| SCHEMBL2331473 | 0.92 | EPHX2 (0.51) | NAAAEPHX2KEAP1NFE2L2EPHX1 | |
| SCHEMBL5655426 | 0.91 | NAAA (0.68) | NAAAEPHX2KEAP1NFE2L2EPHX1 | |
| SCHEMBL7897834 | 0.91 | NAAA (0.68) | NAAAEPHX2KEAP1NFE2L2EPHX1 | |
| SCHEMBL9831902 | 0.89 | NAAA (0.60) | NAAAEPHX2KEAP1NFE2L2EPHX1 | |
| SCHEMBL3199095 | 0.88 | NAAA (0.53) | NAAAEPHX2KEAP1NFE2L2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098207-B2 | Imidazotriazinones and the use thereof | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-29 | — | — | US | disclosed |
| US-20050267112-A1 | Novel imidazotriazinones and the use thereof | BAYER AKTIENGESELLSCHAFT (US) | 2005-12-01 | — | — | US | disclosed |
| US-6943163-B2 | 7-Alkyl and cycloalkyl-substituted imidazotriazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2005-09-13 | — | — | US | disclosed |
| US-6878708-B2 | Imidazotriazinones and the use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2005-04-12 | — | — | US | disclosed |
| US-20050049250-A1 | 7-Aikyl and cycloalkyl-substituted imidazotriazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2005-03-03 | — | — | US | disclosed |
| US-6838459-B1 | 7-alkyl-and cycloalkyl-substituted imidazotriazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2005-01-04 | — | — | US | disclosed |
| US-20040097498-A1 | Novel imidazotriazinones and the use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2004-05-20 | — | — | US | disclosed |
| US-6476029-B1 | 7-alkyl- and cycloalkyl-substituted imidazotriazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2002-11-05 | — | — | US | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097498-A1 | Novel imidazotriazinones and the use thereof | CYP4F3, CYP4F2, CYP3A7 | NAAA 3998/4885EPHX2 2796/4885KEAP1 2014/4885 |
| US-20050267112-A1 | Novel imidazotriazinones and the use thereof | CYP3A7, CYP4F2, CYP4F3 | NAAA 3846/4885EPHX2 2564/4885KEAP1 2606/4885 |
| US-20050049250-A1 | 7-Aikyl and cycloalkyl-substituted imidazotriazinones | PDE3A, PDE2A, PDE3B | NAAA 723/4885EPHX2 1994/4885KEAP1 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.